Market research
AXNX Axonics Modulation Technologies Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 72
- Dividend yield
- Not available
- Beta
- 0.83
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US05465P1012
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 72
- Dividend yield
- Not available
- Beta
- 0.83
About
About Axonics Modulation Technologies Inc
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. As of November 15, 2024, Axonics, Inc. operates as a subsidiary of Boston Scientific Corporation.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AXNX discussion.
5 years, 4 months ago
Axonics Modulation Technologies, Inc is currently in a long term uptrend where the price is trading 18.8% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.4.
Axonics Modulation Technologies, Inc's total revenue rose by 249.7% to $35M since the same quarter in the previous year.
Its net income has increased by 50.1% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.9% to $-29M since the same quarter in the previous year.
Based on the above factors, Axonics Modulation Technologies, Inc gets an overall score of 4/5.